Lumakras
(Sotorasib)ApprovedSmall molecule
AmgenSotorasib is used to treat a specific type of lung cancer (non-small cell lung cancer) in patients whose cancer cells have a particular genetic mutation called KRAS G12C. It works by blocking the abnormal protein that causes these cancer cells to grow.[2] Lumakras is currently approved and in use across 21 indications[4].[1]
Lumakras is one of 475 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.
21
Indications
48
Total Trials
25
Active Trials
474
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 21 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lumakras
AmgenApproved
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Bisphosphonate
AmgenPreclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer8 trials
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting·—·Phase 1·NCT06249282·15 enrolled
Show 5 more trials
Advanced NSCLC3 trials
Tics3 trials
Patients With Advanced Solid Tumors2 trials
28 more indications
Metastatic Colorectal Cancer2 trials
Solid Tumor2 trials
Hepatic Impairment1 trial
Lung Cancer1 trial
Erectile Dysfunction1 trial
Second-line Treatment1 trial
NSCLC1 trial
Pancreas Cancer1 trial
Thoracic Tumors1 trial
Locally Advanced or Metastatic NSCLC1 trial
Pancreatic Adenocarcinoma1 trial
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Not yet recruiting·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT06892054·15 enrolled
Clinical Trial1 trial
Solid Tumor Malignancies1 trial
Solid Tumor Cancers1 trial
Statin1 trial
Chemoradiotherapy1 trial
Advanced Malignant Solid Neoplasm1 trial
Colorectal Cancer1 trial
Lung Carcinoma1 trial
Non-small Cell Lung Cancer (NSCLC)1 trial
Advanced Lung Non-Small Cell Carcinoma1 trial
Colorectal Cancer (CRC)1 trial
Regulatory
FDA Approval Timeline[5]
May 28, 2021
LUMAKRAS
NDA NDA214665
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lumakras drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sotorasib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]